Guangdong Jianxin Pharmaceutical Co., Ltd.

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of acipimox capsule test formulation (specification: 0.25g, applicant: Guangdong Jianxin Pharmaceutical Co., Ltd.) and reference formulation (trade name: OLBETAM®, specification: 0.25g, licensee: Pfizer Limited) after single oral dose in healthy Chinese adult subjects under fasting and postprandial conditions. Secondary study objectives To study the safety of acipimox capsule test formulation (specification: 0.25g) and reference formulation (trade name: OLBETAM®, specification: 0.25g) in healthy Chinese adult subjects.

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of flupentixol-melitracen tablets (specification: each tablet contains 0.5 mg flupentixol and 10 mg melitracen, applicant: Guangdong Jianxin Pharmaceutical Co., Ltd.) and the reference formulation (trade name: Deanxit®, specification: 0.5 mg flupentixol and 10 mg melitracen/tablet, licensee: H. Lundbeck A/S) in healthy Chinese adult subjects after a single oral dose under fasting and postprandial conditions. Secondary study objectives To study the safety of the test formulation of flupentixol-melitracen tablets (specification: each tablet contains 0.5 mg flupentixol and 10 mg melitracen) and the reference formulation (trade name: Deanxit®, specification: 0.5 mg flupentixol and 10 mg melitracen/tablet) in healthy Chinese adult subjects.